Aida Pharmaceuticals, Inc.

Total Valuation

Aida Pharmaceuticals, Inc. carries a market capitalization of 8,101.00, placing it among publicly traded companies globally. Its enterprise value stands at 52.08M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Aida Pharmaceuticals, Inc. currently has 27.00M shares outstanding.

Valuation Ratios

Aida Pharmaceuticals, Inc. trades at a trailing price-to-earnings ratio of 16.45. The price-to-sales ratio is 0.31, and the price-to-book ratio stands at 4.59.

Enterprise Valuation

On an enterprise value basis, Aida Pharmaceuticals, Inc. trades at an EV/EBITDA multiple of 21.06 and an EV/FCF ratio of 4.56. The EV/Sales ratio of 1.27 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 55,405.01 provides insight into valuation relative to core operating earnings.

Financial Position

Aida Pharmaceuticals, Inc. maintains a current ratio of 0.73, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Aida Pharmaceuticals, Inc. posts a return on equity of -54.24 and a return on invested capital of 9.26.

Taxes

Over the trailing twelve months, Aida Pharmaceuticals, Inc. has paid -1.12M in income taxes, reflecting an effective tax rate of 55.17.

Stock Price Statistics

Aida Pharmaceuticals, Inc.'s stock has gained approximately 50% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.

Income Statement

Over the trailing twelve months, Aida Pharmaceuticals, Inc. generated 40.95M in revenue and converted that into -2.09M in net income, yielding earnings per share of -0.08. EBITDA reached 2.47M, while operating income came in at 940.00.

Balance Sheet

Aida Pharmaceuticals, Inc. holds 9.98M in cash and equivalents against 41.16M in total debt, resulting in a net debt position of 32.88M. Total book value stands at 2.77M, with working capital of -12.09M providing operational flexibility.

Cash Flow

Aida Pharmaceuticals, Inc. produced 6.17M in operating cash flow over the past twelve months. After subtracting -5.26M in capital expenditures, free cash flow totaled 911,251.00 - equivalent to 0.03 per share.

Margins

Aida Pharmaceuticals, Inc. operates with a gross margin of 55.66, reflecting its pricing power and cost economics. The operating margin of 0.00 and net profit margin of -5.11 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Aida Pharmaceuticals, Inc.'s most recent stock split took place on November 30, 2005 with a 4:5 split ratio.

Scores

Aida Pharmaceuticals, Inc. posts an Altman Z-Score of 0.70, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.